Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Subjects Clear all
Completed Phase 1 Interventional

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

NCT06050928
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Oral EP262
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 25, 2026, 1:11 PM EDT
Terminated Phase 1 Interventional Results available

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

NCT02751528
View directory record Official record
Conditions
Cancer
Interventions
ETBX-021
Biological
Lead sponsor
NantBioScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
El Segundo, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 1 Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

NCT00361634
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01597492
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab plus Early Vaccination, Belimumab plus Late Vaccination
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Shreveport, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 25, 2026, 1:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lynne Cohen Consortium Project: Multi-Center Database/Registry

NCT00776958
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Questionnaire
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 25, 2026, 1:11 PM EDT
Terminated Phase 3 Interventional Results available

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

NCT03115476
View directory record Official record
Conditions
Actinic Keratosis, Squamous Cell Carcinoma
Interventions
ingenol disoxate gel 0.018%, ingenol disoxate gel 0.037%, Vehicle gel
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
Not listed
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
30
States / cities
Hot Springs, Arkansas • Fremont, California • Murrieta, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

NCT04430855
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 4%, SB206 8%, SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
2 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Ana, California • Thornton, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects

NCT03997851
View directory record Official record
Conditions
Pruritus
Interventions
Acetaminophen, Carbomer 980
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 25, 2026, 1:11 PM EDT
Not yet recruiting Phase 2 Interventional

Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)

NCT07671157
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib
Drug
Lead sponsor
Maryanne Makredes Senna
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 1:11 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

NCT01362712
View directory record Official record
Conditions
Breast Cancer
Interventions
[F18]CP-18 Injection
Radiation
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
21 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Irvine, California • Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

NCT02124239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol mebutate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

NCT02698475
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 1:11 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

NCT01920477
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Ofatumumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

NCT02945657
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MM36 topical ointment, 1%
Drug
Lead sponsor
Medimetriks Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Fremont, California • Irvine, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

NCT02937701
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 710, Infliximab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 25, 2026, 1:11 PM EDT
Not listed Phase 2 Interventional

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

NCT01231802
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eniluracil, 5-Fluorouracil, Leucovorin, Capecitabine
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Gilbert, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Oct 25, 2026, 1:11 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

NCT06544330
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Interventions
SYNCAR-001, STK-009
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
6
States / cities
Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lifting and Tightening of the Face in Subjects With Skin of Darker Color

NCT01368965
View directory record Official record
Conditions
Facial Skin Laxity
Interventions
Ulthera® System treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
30 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chevy Chase, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 25, 2026, 1:11 PM EDT
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 25, 2026, 1:11 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

NCT03393000
View directory record Official record
Conditions
Glioblastoma
Interventions
Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Irvine, California • Redwood City, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

NCT03451422
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Efavaleukin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Anniston, Alabama • Beverly Hills, California • Aventura, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 25, 2026, 1:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison

NCT00841594
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
nitroglycerin 0.9 % (MXQ-503), Nitroglycerin ointment 2%, USP
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 25, 2026, 1:11 PM EDT